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Abstract
Radical cystectomy with pelvic lymphadenectomy is the standard treatment for muscle-invasive
bladder cancer. However, the high recurrence rates and high death rate from metastases after radical
cystectomy for locally advanced bladder cancer emphasize the high risk of occult distant disease. To
improve patient survival, multimodal therapy whereby chemotherapy and surgery are used in concert
with each other is necessary. The preponderance of data suggests that neoadjuvant chemotherapy
offers patients a clear – albeit small – survival advantage, whereas the data for adjuvant chemotherapy
are less convincing. Currently, trials to improve the results of such neoadjuvant therapy using biologic
targets in conjunction with cytotoxic regimens are under way.
Introduction and context
Radical cystectomy with extended pelvic lymphadenect-
omy is the mainstay of treatment of muscle-invasive
urothelial carcinoma of the bladder (UCB) [1]. However,
in a number of patients, especially those with high-risk
disease, such as pathologic stage T3 or T4, and those with
lymph node metastases, surgery alone is not sufficient.
Five-year overall survival rates for patients with pT3a,
pT3b, pT4, and pN
+ treated with surgery alone are 78%,
62%, 50%, and 35%, respectively [1]. It is believed that
micrometastases present at the time of cystectomy [2]
contribute to subsequent local and distant recurrences
and mortality from UCB. As a result, both neoadjuvant
and adjuvant chemotherapy clinical trials have been
conducted in order to improve the clinical outcomes of
this group of patients.
Neoadjuvant chemotherapy has several potential advan-
tages. It has the potential of treating micrometastases
that could be present at the initial diagnosis of UCB [2].
In addition, many patients tolerate chemotherapy better
when it is given prior to radical cystectomy. Patients with
locally advanced disease or bulky unresectable disease
can be downstaged with neoadjuvant chemotherapy,
and this could render surgery technically feasible. On the
other hand, opponents of this paradigm suggest that it is
difficult to assess the true pathologic stage of disease on
the basis of clinical factors (such as grade and stage from
TURBT [transurethral resection of bladder tumor] and
bimanual physical examination before) and that, as a
result of such an assessment, some patients could receive
unnecessary chemotherapy. In fact, up to one-third of
the cases can be incorrectly staged prior to radical
cystectomy.
Several trials have studied neoadjuvant chemotherapy in
a randomized fashion. The largest trial was an interna-
tional collaboration [3] in which 976 patients with
clinical stage T2 to T4a UCB were randomly assigned to
radical cystectomy or radiotherapy with or without
neoadjuvant chemotherapy (methotrexate, vinblastine,
cisplatin, and folinic acid residue). Patients treated with
chemotherapy had a median survival of 44 months
compared with 37.5 months for upfront cystectomy. In
addition, 3-year overall survival was improved by 5.5%
with chemotherapy (from 50% to 55.5%). This study did
have confounders: radiotherapy was used in almost half
of the patients (instead of radical cystectomy), and no
adriamycin was used. In addition, patients had a short
follow-up of 4 years. More recently, Grossman et al. [4]
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(SWOG) 8710 trial of 307 patients with clinical stage T2
to T4a UCB randomly assigned to radical cystectomy
with or without neoadjuvant MVAC (methotrexate,
vinblastine, adriamycin, and cisplatin). In that study,
patients treated with combination therapy had higher
pT0 rates (38% versus 15%), improved median survival
(77 months versus 46 months), and improved 5-year
overall survival (57% versus 43%) compared with
patients treated with surgery only (P = 0.06 by a two-
sided stratified log-rank test). In 2005, the Advanced
Bladder Cancer (ABC) Meta-analysis Collaboration
conducted a large meta-analysis of 11 neoadjuvant
chemotherapy clinical trials that included 3005 patients.
That study showed that neoadjuvant platinum-based
chemotherapy resulted in a significant survival benefit
(hazard ratio [HR] = 0.86, P = 0.003) with a 13%
reduction in risk of death and a 5-yearabsolute reduction
of disease-specific mortality of 9% and overall mortality
of 5% [5].
Adjuvant chemotherapy (given immediately after
surgery) is another option. The advantage is that the
pathology is ascertained and the stage is accurately
assessed, allowing better selection of patients for
chemotherapy. In theory, this would minimize the
number of patients who receive unnecessary therapy.
On the other hand, surgery and its associated potential
complications could prevent some patients from
receiving adjuvant chemotherapy in a timely fashion.
Of the 10 or so trials performed to date, only 3 have
shown a benefit to adjuvant chemotherapy. Skinner
et al. [6] randomly assigned 91 patients with stage pT3
t oT 4 ,N 0t oN 2U C Bt os u r g e r yw i t ho rw i t h o u t
adjuvant chemotherapy (mainly with cisplatin, adria-
mycin, and cyclophosphamide) and found that the
median overall survival rate was higher for patients
treated with chemotherapy (4.3 years versus 2.4 years).
Stöckle et al. [7,8] randomly assigned 49 patients
with stage pT3b to T4a, N0 to N2 UCB to radical
cystectomy with or without chemotherapy with MVAC
or MVEC (epirubicin instead of adriamycin) and on an
updated intention-to-treat analysis [9] showed a
median progression-free survival of 66.9 months and
a median overall survival of 35.1 months for the
adjuvant chemotherapy group (compared with 11.6
months and 20.4 months, respectively, for the surgery-
only group). Freiha et al. [10] randomly assigned 50
patients with stage pT3b to T4, N0 to N2 UCB to
surgery with or without adjuvant CMV (cisplatin,
methotrexate, and vinblastine) chemotherapy and
noted that progression-free survival was higher in
patients treated with chemotherapy (37 months versus
12 months). The ABC Meta-analysis Collaboration also
performed a meta-analysis for adjuvant chemotherapy
that included six clinical trials with 491 patients.
Although that analysis showed a 25% relative reduction
in mortality (HR = 0.75, P = 0.019) and 3-year absolute
reduction in mortality of 9% in patients treated with
adjuvant therapy, the power of the meta-analysis is
limited since those trials were generally small and
underpowered to investigate small differences in survi-
val, some trials were stopped early, some patients did
not receive salvage therapy, and others did not receive
their allocated treatment [11].
Recent advances
More recently, trials that include large numbers of
patients have been launched. A group from Italy
recently reported their results on adjuvant versus
salvage (given at the time of clinical relapse) che-
motherapy (with gemcitabine and cisplatin) after
radical cystectomy in patients with pT2G3 to T4 N0
to N2 disease and found that 3-year overall survival
rates were 48% with adjuvant chemotherapy and 67%
with salvage chemotherapy, and these rates were not
statistically different [12]. Unfortunately, that trial
closed early because of poor accrual and reported on
only 194 patients instead of the planned 610. The
EORTC (European Organization for Research and
Treatment of Cancer) 30994 trial (NCT00028756)
randomly assigned patients to receive early (within
90 days of cystectomy) versus delayed (at the time of
clinical relapse) chemotherapy using MVAC, dose-
dense MVAC, or GC (gemcitabine plus cisplatin), and
the final results are awaited.
Millikan et al. [13] reported on a trial in which 140
patients with stage T2 with lymphovascular invasion or
stages cT3 to T4a were enrolled. One group received two
cycles of neoadjuvant MVAC, followed by surgery, and
then three more cycles of MVAC, and the second group
received five cycles of MVAC only after surgery. Overall
survival was not different between the two strategies,
suggesting that the sequence of chemotherapy in relation
to surgery might not be as important as the fact that
multimodal therapy is needed.
Several trials with the aim of improving survival in
patients with high-risk non-metastatic UCB are cur-
rently ongoing. Erlotinib is currently being used prior
to radical cystectomy in two phase II clinical trials in
patients with muscle-invasive but resectable disease.
The first trial (NCT00749892) is studying the pT0 rate
after radical cystectomy as a primary endpoint, and the
second trial (NCT00380029) aims at investigating the
gene expression changes noted at radical cystectomy
after a 1-month treatment with erlotinib. A pilot trial
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started and aims to study feasibility in 25 patients
who will undergo radical cystectomy after 4 weeks of
dasatinib. In addition, two phase II trials are currently
enrolling patients with muscle-invasive UCB and
treating them with gemcitabine/cisplatin/sunitinib
prior to radical cystectomy. The aim of the first trial
(NCT00859339) is to assess the pT0 rate, whereas the
second trial (NCT00847015) aims to assess the pT0
rate along with regimen safety. In a recent clinical trial
of adjuvant MVAC [14] (NCT00005047), patients were
randomly assigned on the basis of p53 staining status
in radical cystectomy specimens. Patients who had
altered p53 status (defined as nuclear immunoreactivity
of greater than 10%) were randomly assigned (stratified
byage,grade,stage,andp21status)toeitherthreecycles
of MVAC or observation, whereas patients with normal
p53 underwent observation. Owing to a lack of efficacy,
accrual for this study has stopped early (only 114
patients with positive p53 underwent random
assignment).
Implications for clinical practice
Although the current data suggest that neoadjuvant
chemotherapy should be standard practice, this para-
digm has been slow to be adopted, even in the US; a
recent report suggests that only 11.6% of eligible patients
receive chemotherapy (10.4% adjuvant therapy and
1.2% neoadjuvant therapy) [15]. This is partly due to
the desire of patients to avoid overtreatment. Thus,
currently, at MD Anderson Cancer Center, we prefer to
use a risk-adapted approach (Figure 1) to patients with
muscle-invasive UCB by selecting patients who are at
high risk of death from disease to receive neoadjuvant
chemotherapy. Patients who are at low risk, defined as
clinical stage CIS (carcinoma in situ), Ta, T1, or T2 only
(in the absence of lymphovascular invasion, non-
urothelial or variant histology, and hydronephrosis),
are offered upfront cystectomy. Clearly, however, future
focus should be on improving the preoperative selection
criteria for chemotherapy, using both clinical and
molecular methods, in order to appropriately allocate
patients to chemotherapy. Encouraging clinicians to
Figure 1. The MD Anderson Cancer Center algorithm for management of surgically resectable bladder cancer
Risk-adapted approach to patients with muscle-invasive bladder cancer by selecting patients who are at high risk of death from disease to receive neoadjuvant
chemotherapy. Patients who are at low risk, defined as clinical stage CIS (carcinoma in situ), Ta, T1, or T2 only (in the absence of lymphovascular
invasion, non-urothelial or variant histology, and hydronephrosis), are offered upfront cystectomy.
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accrual, quick completion, and ultimately the success of
these trials.
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